{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:17:09Z","timestamp":1771841829189,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.thromres.2013.08.004","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T22:42:25Z","timestamp":1376088145000},"page":"444-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity"],"prefix":"10.1016","volume":"132","author":[{"given":"Xiaoqi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2013.08.004_bb0005","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.jacc.2011.02.011","volume":"57","author":"Wright","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.08.004_bb0010","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","article-title":"Variability in platelet responsiveness to clopidogrel among 544 individuals","volume":"45","author":"Serebruany","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.08.004_bb0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1538-7836.2010.03809.x","article-title":"Clopidogrel, Vascular IEM-aSG. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis","volume":"8","author":"Combescure","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0020","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.08.004_bb0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2013.08.004_bb0030","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2010-08-263111","article-title":"The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects","volume":"117","author":"Cattaneo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2013.08.004_bb0035","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Working Group on High On-Treatment Platelet R. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.08.004_bb0040","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2013.08.004_bb0045","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0050","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1538-7836.2008.03050.x","article-title":"The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects","volume":"6","author":"Umemura","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0055","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.08.004_bb0060","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.08.004_bb0065","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2007.02722.x","article-title":"Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects","volume":"5","author":"Fontana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0070","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients","volume":"17","author":"Giusti","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.thromres.2013.08.004_bb0075","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/clpt.2008.20","article-title":"The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance","volume":"84","author":"Kim","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.08.004_bb0080","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.amjcard.2007.11.065","article-title":"Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome","volume":"101","author":"Frere","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2013.08.004_bb0085","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.08.004_bb0090","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2013.08.004_bb0095","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.08.004_bb0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.thromres.2013.08.004_bb0105","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","article-title":"No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting","volume":"32","author":"Sibbing","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2013.08.004_bb0110","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/j.1538-7836.2011.04409.x","article-title":"Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study","volume":"9","author":"Fontana","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0115","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCGENETICS.111.960112","article-title":"Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement","volume":"4","author":"Trenk","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.thromres.2013.08.004_bb0120","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2217\/pgs.11.73","article-title":"Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention","volume":"12","author":"Rideg","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.thromres.2013.08.004_bb0125","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCINTERVENTIONS.111.963025","article-title":"CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients","volume":"4","author":"Hulot","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.thromres.2013.08.004_bb0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/clpt.2011.194","article-title":"Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response","volume":"90","author":"Lewis","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.08.004_bb0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.2011.221","article-title":"Predicting clopidogrel response using DNA samples linked to an electronic health record","volume":"91","author":"Delaney","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.08.004_bb0140","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1538-7836.2011.04457.x","article-title":"Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention","volume":"9","author":"Campo","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0145","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2011.1529","article-title":"Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis","volume":"306","author":"Cayla","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.08.004_bb0150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/clpt.2011.193","article-title":"Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction","volume":"90","author":"Simon","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.08.004_bb0155","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0021-9150(97)00197-4","article-title":"Why plasma should not be used to study paraoxonase","volume":"136","author":"Mackness","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2013.08.004_bb0160","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/nm.2386","article-title":"Paraoxonase-1 and clopidogrel efficacy","volume":"17","author":"Camps","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.thromres.2013.08.004_bb0165","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/clpt.2011.226","article-title":"PON1 Q192R and clopidogrel: a case of the winner's curse or inadequate replication?","volume":"90","author":"Talameh","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2013.08.004_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2004.07.002","article-title":"The difference between clopidogrel responsiveness and posttreatment platelet reactivity","volume":"115","author":"Samara","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2013.08.004_bb0175","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0032-1301417","article-title":"High platelet reactivity and antiplatelet therapy resistance","volume":"38","author":"Linden","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0180","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.109.192663","volume":"120","author":"Kushner","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.08.004_bb0185","first-page":"6","article-title":"2009 update of the ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction and guidelines on percutaneous coronary intervention: what should we change in clinical practice?","volume":"120","author":"King","year":"2010","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.thromres.2013.08.004_bb0190","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/MJT.0b013e3181727d06","article-title":"Practical implications of ACC\/AHA 2007 guidelines for the management of unstable angina\/non-ST elevation myocardial infarction","volume":"17","author":"Patel","year":"2010","journal-title":"Am J Ther"},{"key":"10.1016\/j.thromres.2013.08.004_bb0195","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.08.004_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2013.05.006","article-title":"Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients","author":"Zhang","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2013.08.004_bb0205","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.08.004_bb0210","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.2174\/138161209789057977","article-title":"Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides","volume":"15","author":"Petraki","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.thromres.2013.08.004_bb0215","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1146\/annurev.med.54.101601.152421","article-title":"Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism","volume":"54","author":"Costa","year":"2003","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.thromres.2013.08.004_bb0220","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1476-5381.2012.01946.x","article-title":"The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro","volume":"166","author":"Ancrenaz","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.thromres.2013.08.004_bb0225","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1021\/tx2004085","article-title":"Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer","volume":"25","author":"Dansette","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.thromres.2013.08.004_bb0230","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/j.1538-7836.2011.04541.x","article-title":"Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy","volume":"9","author":"Tselepis","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0235","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1538-7836.2012.04756.x","article-title":"Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis","volume":"10","author":"Reny","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0240","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s00109-003-0481-4","article-title":"Paraoxonase gene polymorphisms, oxidative stress, and diseases","volume":"81","author":"Li","year":"2003","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.thromres.2013.08.004_bb0245","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.299.11.1265","article-title":"Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk","volume":"299","author":"Bhattacharyya","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.08.004_bb0250","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1538-7836.2007.02462.x","article-title":"Indices of platelet activation and the stability of coronary artery disease","volume":"5","author":"Linden","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.08.004_bb0255","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00228-012-1446-8","article-title":"Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention","volume":"69","author":"Tang","year":"2013","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813003332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813003332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T09:48:16Z","timestamp":1715852896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813003332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0049384813003332"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.08.004","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}